Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | GAA | P10253 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104674 | 0.83 | NPSR1 (0.63) | NPSR1ALDH1A1GAAATMCSF1R | |
| SCHEMBL7833448 | 0.81 | CHEK1 (0.50) | NPSR1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4078674 | 0.78 | GAA (0.44) | NPSR1ALDH1A1GAAPOLBKMT2A | |
| SCHEMBL3539636 | 0.78 | CSF1R (0.61) | NPSR1ALDH1A1GAAHPGDCSF1R | |
| Trifluoroacetic Acid SCHEMBL3070914 | 0.77 | GAA (0.72) | NPSR1ALDH1A1GAAHPGDPOLB | |
| SCHEMBL8828664 | 0.76 | KCNQ2 (0.47) | NPSR1ALDH1A1GAAPOLBKMT2A | |
| SCHEMBL23507384 | 0.75 | ALDH1A1 (0.56) | NPSR1ALDH1A1GAAHPGDPOLB | |
| SCHEMBL8828431 | 0.74 | CYP2D6 (0.48) | NPSR1ALDH1A1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL3543649 | 0.74 | CSF1R (0.66) | NPSR1ALDH1A1GAAHPGDCSF1R | |
| Trifluoroacetic Acid SCHEMBL3070908 | 0.72 | NPC1 (0.55) | NPSR1ALDH1A1GAAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | claimed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | claimed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | claimed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | claimed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | NPSR1 797/4885ALDH1A1 4731/4885GAA 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.